Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Doctors at the hospital highlighted that robotic-assisted surgery enhances precision through superior 3D visualisation and improved instrument flexibility
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Subscribe To Our Newsletter & Stay Updated